Glp3-R Research Peptide

GLP3-R Research Peptide (what it actually is)

GLP3-R is a commercial/research label used in peptide markets for a compound that is generally identified as a retatrutide-class triple agonist peptide.

It is described in research sources as a synthetic peptide that targets three metabolic receptors:

• GLP-1 receptor (GLP-1R) → appetite & insulin signaling
• GIP receptor (GIPR) → glucose metabolism & satiety
• Glucagon receptor (GCGR) → energy expenditure & fat metabolism (ZynoPep)

This is the same broader mechanism class as retatrutide (LY3437943), a investigational triple-agonist studied for obesity and metabolic disease pathways. (CompoundReview)

Important clarification

• “GLP3-R” is NOT an official endogenous hormone or medically approved drug name
• It is a market/labeling term used in research peptide catalogs
• The scientifically recognized name in literature is retatrutide-class triple agonist

What researchers study it for

Across published and preclinical discussions, GLP3-R / retatrutide-class peptides are studied for:

• Appetite regulation
• Weight loss mechanisms
• Insulin sensitivity
• Blood glucose control
• Energy expenditure and metabolism (CompoundReview)

Regulatory status

• Investigational / research-only
• Not FDA-approved for general medical use
• Human data exists for retatrutide in clinical trials, but products labeled GLP3-R in the market are typically research-grade labeling, not standardized pharmaceuticals

Bottom line

“GLP3-R” is basically a marketing shorthand for a triple-agonist metabolic peptide class (retatrutide-type compounds) rather than a distinct approved drug.